Nature Publishing Group

SHERPA: Yellow

People

  1. Reuter
    Reuter
  2. Ladanyi
    Ladanyi
  3. Al-Ahmadie
    Al-Ahmadie
  4. Fine
    Fine
  5. Gopalan
    Gopalan
  6. Tickoo
    Tickoo
  7. Antonescu
    Antonescu
  8. Shia
    Shia
  9. Chen
    Chen
  10. Weigelt
    Weigelt

Groups

  1. GSK Faculty (2494)
  2. Department of Medicine (2041)
  3. Department of Pathology and Laboratory Medicine (1928)
  4. Sloan Kettering Institute Faculty (1418)
  5. Sloan Kettering Institute Postdocs (1254)
  6. Center for Hematologic Malignancies (1092)
  7. Hematologic Malignancies, Division of (998)
  8. Solid Tumor Oncology Division (989)
  9. Center for Molecular Imaging and Biotechnology (CMIB) (962)
  10. Tow Center for Developmental Oncology (TCDO) (890)
Search Within
Formats
  1. Journal Article (3618)
  2. Meeting Abstract (2162)
  3. Review (189)
  4. Editorial (100)
  5. Research Letter (96)
  6. Correspondence (30)
  7. Conference Paper (23)
  8. Guidelines (13)
  9. Miscellaneous (9)
Groups
  1. GSK Faculty (2494)
  2. Department of Medicine (2041)
  3. Department of Pathology and Laboratory Medicine (1928)
  4. Sloan Kettering Institute Faculty (1418)
  5. Sloan Kettering Institute Postdocs (1254)
  6. Center for Hematologic Malignancies (1092)

More Groups

People
  1. Victor Reuter (297)
  2. Marc Ladanyi (225)
  3. Hikmat Al-Ahmadie (197)
  4. David Klimstra (195)
  5. Robert Soslow (165)
  6. Samson Fine (159)

More People

Years
  1. 2025 (290)
  2. 2024 (363)
  3. 2023 (320)
  4. 2022 (354)
  5. 2021 (316)
  6. 2020 (374)

More Years

Publications
  1. Laboratory Investigation (1890)
  2. Nature (597)
  3. Nature Communications (449)
  4. Bone Marrow Transplantation (379)
  5. Leukemia (281)
  6. Nature Medicine (244)

More Publications

Results (6240)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DNA aptamers that modulate biological activity of model neurons
    Journal Article

    Rolli, J.; Pearson, K.; Wilbanks, B.; Hrstka, S. C. L.; Minotti, A. P.; Studer, L.; Warrington, A. E.; Staff, N. P.; Maher, L. J. 3rd
    Molecular Therapy - Nucleic Acids (2024)

    Fulltext@MSK | Save
  • Fungal symbiont transmitted by free-living mice promotes type 2 immunity
    Journal Article

    Liao, Y.; Gao, I. H.; Kusakabe, T.; Lin, W. Y.; Grier, A.; Pan, X.; Morzhanaeva, O.; Shea, T. P.; Yano, H.; Karo-Atar, D.; more...
    Nature (2024)

    Fulltext@MSK | Save
  • Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
    Journal Article

    Merz, M.; Dima, D.; Hashmi, H.; Ahmed, N.; Stölzel, F.; Holderried, T. A. W.; Fenk, R.; Müller, F.; Tovar, N.; Oliver-Cáldes, A.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors
    Meeting Abstract

    Schoenfeld, A. J.; Warner, A. B.; Thomas, S. S.; Hamid, O.; In, G. K.; Shoushtari, A. N.; Samhouri, Y.; Hari, P.; Ramsingh, G.; Prabhakar, P.; more...
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • CAR T-cell-derived TNF drives cytokine release syndrome and enhances M1 macrophage differentiation
    Meeting Abstract

    Lindenbergh, P. L.; Giavridis, T.; Vivier, O.; Lopez, M.; Dobrin, A.; Sadelain, M.
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • Safety, tolerability, and clinical assessment of bemdaneprocel for Parkinson's disease: Results up to 18 months from a phase 1 study
    Meeting Abstract

    Henchcliffe, C.; Sarva, H.; Lozano, A.; Fasano, A.; Kalia, S.; Yu, K. K. H.; Brennan, C.; Stemple, W.; Abid, N.; Yountz, M.; more...
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • CRISPR-Cas9 genetic targeting of metastatic pancreatic cancer
    Meeting Abstract

    Bowland, K.; Lai, J.; Teh, S. S. K.; Bennett, A.; Skaist, A.; Zhang, Y.; Thompson, E.; Wheelan, S. J.; Hruban, R. H.; Karchin, R.; more...
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • Loss of heterozygosity is low for specific HLA alleles in cancer patients with driver mutations
    Meeting Abstract

    Roy, C.; Sewastianik, T.; Halvey, P.; Montesion, M.; Jindal, A.; Vallaster, M.; Lam, H.; Garrity, S.; Shapiro, G.; Klebanoff, C. A.; more...
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • THRIVE(TM) non-viral targeted transgene knock-in platform generates specific and potent TCR T cell products for the treatment of solid cancers
    Meeting Abstract

    Narayan, S.; Swanson, N.; Drain, A.; Gareau, K.; Rouillard, N.; Liang, J.; Liu, H. W.; Brown, L.; Lamothe, R.; Greenberg, P. D.; more...
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: A retrospective cohort study
    Journal Article

    Lee, Y. H. A.; Hui, J. M. H.; Leung, C. H.; Tsang, C. T. W.; Hui, K.; Tang, P.; Chan, J. S. K.; Dee, E. C.; Ng, K.; McBride, S.; more...
    Prostate Cancer and Prostatic Diseases (2024)

    Fulltext@MSK | Save